Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03355365 (ClinicalTrials.gov)	September 21, 2018	14/11/2017	Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis	Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally	Multiple Sclerosis	Biological: Intrathecal MSC-NP injection;Other: Intrathecal saline injection	Tisch Multiple Sclerosis Research Center of New York	NULL	Active, not recruiting	18 Years	65 Years	All	50	Phase 2	United States
2	NCT03822858 (ClinicalTrials.gov)	February 2011	24/1/2019	Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis	Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally	Multiple Sclerosis	Drug: Intrathecal MSC-NP injection	Tisch Multiple Sclerosis Research Center of New York	NULL	Available	18 Years	70 Years	All			United States